<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00192218</url>
  </required_header>
  <id_info>
    <org_study_id>MI-MA004</org_study_id>
    <nct_id>NCT00192218</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Effectiveness of FluMist Vaccination in a School-Based Intervention Program</brief_title>
  <official_title>A Phase IV Study to Evaluate the Effectiveness of Flumist (Influenza Vaccine, Live Intranasal) Vaccination in a School-Based Intervention Program</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <brief_summary>
    <textblock>
      To measure the effectiveness of influenza vaccination in school children by comparing,
      between target(i.e., children are offered FluMist) and control (i.e., children are not
      offered FluMist) school families.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">April 2005</completion_date>
  <primary_completion_date type="Actual">April 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the families of children in the target schools with families of children in the control schools with respect to workdays lost by adults and school days lost by children.</measure>
    <time_frame>7 days after each vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absenteeism - To compare the families of children in the target schools to those in the control schools with respect to the overall increase in absenteeism during the influenza outbreak, using aggregated (summary) absentee rates.</measure>
    <time_frame>between outbreak and non-outbreak weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Herd Community - To compare unvaccinated children in the target schools to the children in the control schools with respect to changes in absentee rates between outbreak weeks and non-outbreak weeks.</measure>
    <time_frame>between outbreak and non-outbreak weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3022</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FluMist</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>FluMist</intervention_name>
    <description>0.5 ml of vaccine intranasally (0.25 ml in each nostril) which contains approximately 107 TCID50 of each type</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy children enrolled in the target schools.

          -  Written informed consent obtained from the child's parent(s) if they agree to
             participate.

        Exclusion Criteria:

          -  History of severe hypersensitivity (anaphylactic response) to egg products or previous
             FluMist

          -  FluMist is licensed exclusively for use in healthy individuals age 5-49 years.
             Therefore children for whom annual receipt of inactivated influenza vaccine for
             specific medical condition(s) is recommended will not be eligible. These conditions
             include:

          -  Asthma, other chronic pulmonary diseases, kidney disease, metabolic disease, heart
             disease, or hemoglobinopathy

          -  Immunosuppression of child

          -  Severe immunosuppression of a household member

          -  Pregnancy

          -  Past history of Guillian-Barre Syndrome

          -  Aspirin therapy within 1 month prior to FluMist or the anticipated use of aspirin
             containing products for one month after FluMist administration

          -  Administration of any inactivated vaccine within 2 weeks or any live vaccine within 4
             weeks prior to receipt of FluMist

          -  Received anti-influenza medication in the past 48 hours

          -  Fever in the past 72 hours

          -  Moderate to severe nasal congestion (inability to breathe through the nose) or acute
             phase URI symptoms until the congestion has improved
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Walker, MD</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Division of General Pediatrics, University of Maryland School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Allergy and Infectious Diseases, University of Washington School of Medicine</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>September 19, 2008</last_update_submitted>
  <last_update_submitted_qc>September 19, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2008</last_update_posted>
  <responsible_party>
    <name_title>Robert Walker, MD</name_title>
    <organization>MedImmune LLC</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

